Biomarin Pharmaceutical Stock Current Valuation
| BMRN Stock | USD 71.24 0.36 0.50% |
Valuation analysis of Biomarin Pharmaceutical helps investors to measure Biomarin Pharmaceutical's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. At this time, Biomarin Pharmaceutical's Enterprise Value Over EBITDA is very stable compared to the past year. As of the 22nd of March 2025, Enterprise Value Multiple is likely to grow to 19.61, while Enterprise Value is likely to drop about 9.8 B. Fundamental drivers impacting Biomarin Pharmaceutical's valuation include:
Overvalued
Today
Please note that Biomarin Pharmaceutical's price fluctuation is very steady at this time. Calculation of the real value of Biomarin Pharmaceutical is based on 3 months time horizon. Increasing Biomarin Pharmaceutical's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Biomarin Pharmaceutical is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Biomarin Stock. However, Biomarin Pharmaceutical's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 71.24 | Real 52.72 | Target 97.66 | Hype 71.24 | Naive 71.38 |
The intrinsic value of Biomarin Pharmaceutical's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Biomarin Pharmaceutical's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Biomarin Pharmaceutical helps investors to forecast how Biomarin stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Biomarin Pharmaceutical more accurately as focusing exclusively on Biomarin Pharmaceutical's fundamentals will not take into account other important factors: Biomarin Pharmaceutical Company Current Valuation Analysis
Biomarin Pharmaceutical's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Biomarin Pharmaceutical Current Valuation | 13.06 B |
Most of Biomarin Pharmaceutical's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Biomarin Pharmaceutical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Biomarin Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Biomarin Pharmaceutical is extremely important. It helps to project a fair market value of Biomarin Stock properly, considering its historical fundamentals such as Current Valuation. Since Biomarin Pharmaceutical's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Biomarin Pharmaceutical's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Biomarin Pharmaceutical's interrelated accounts and indicators.
Click cells to compare fundamentals
Biomarin Current Valuation Historical Pattern
Today, most investors in Biomarin Pharmaceutical Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Biomarin Pharmaceutical's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Biomarin Pharmaceutical current valuation as a starting point in their analysis.
Biomarin Pharmaceutical Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Biomarin Pharmaceutical has a Current Valuation of 13.06 B. This is 9.1% lower than that of the Biotechnology sector and 181.05% higher than that of the Health Care industry. The current valuation for all United States stocks is 21.46% higher than that of the company.
Biomarin Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Biomarin Pharmaceutical's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Biomarin Pharmaceutical could also be used in its relative valuation, which is a method of valuing Biomarin Pharmaceutical by comparing valuation metrics of similar companies.Biomarin Pharmaceutical is currently under evaluation in current valuation category among its peers.
Biomarin Pharmaceutical ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Biomarin Pharmaceutical's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Biomarin Pharmaceutical's managers, analysts, and investors.Environmental | Governance | Social |
Biomarin Fundamentals
| Return On Equity | 0.0805 | ||||
| Return On Asset | 0.0515 | ||||
| Profit Margin | 0.15 % | ||||
| Operating Margin | 0.34 % | ||||
| Current Valuation | 13.06 B | ||||
| Shares Outstanding | 190.78 M | ||||
| Shares Owned By Insiders | 0.96 % | ||||
| Shares Owned By Institutions | 98.62 % | ||||
| Number Of Shares Shorted | 4.47 M | ||||
| Price To Earning | 220.73 X | ||||
| Price To Book | 2.40 X | ||||
| Price To Sales | 4.79 X | ||||
| Revenue | 2.85 B | ||||
| Gross Profit | 2.27 B | ||||
| EBITDA | 650.53 M | ||||
| Net Income | 426.86 M | ||||
| Cash And Equivalents | 1.27 B | ||||
| Cash Per Share | 6.85 X | ||||
| Total Debt | 602.71 M | ||||
| Debt To Equity | 0.24 % | ||||
| Current Ratio | 5.15 X | ||||
| Book Value Per Share | 29.66 X | ||||
| Cash Flow From Operations | 572.84 M | ||||
| Short Ratio | 2.98 X | ||||
| Earnings Per Share | 2.20 X | ||||
| Price To Earnings To Growth | 0.49 X | ||||
| Target Price | 96.72 | ||||
| Number Of Employees | 3.04 K | ||||
| Beta | 0.33 | ||||
| Market Capitalization | 13.66 B | ||||
| Total Asset | 6.99 B | ||||
| Retained Earnings | (194.69 M) | ||||
| Working Capital | 2.63 B | ||||
| Current Asset | 1.09 B | ||||
| Current Liabilities | 445.46 M | ||||
| Net Asset | 6.99 B |
About Biomarin Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Biomarin Pharmaceutical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biomarin Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biomarin Pharmaceutical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
When determining whether Biomarin Pharmaceutical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biomarin Pharmaceutical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biomarin Pharmaceutical Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biomarin Pharmaceutical Stock: Check out Biomarin Pharmaceutical Piotroski F Score and Biomarin Pharmaceutical Altman Z Score analysis. To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomarin Pharmaceutical. If investors know Biomarin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomarin Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 6.449 | Earnings Share 2.2 | Revenue Per Share | Quarterly Revenue Growth 0.156 | Return On Assets |
The market value of Biomarin Pharmaceutical is measured differently than its book value, which is the value of Biomarin that is recorded on the company's balance sheet. Investors also form their own opinion of Biomarin Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biomarin Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomarin Pharmaceutical's market value can be influenced by many factors that don't directly affect Biomarin Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomarin Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomarin Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomarin Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.